Inhaler cost analysis
Pro Research Analysisby 
Searched over 200M research papers
Inhaler Cost Analysis: Trends and Key Drivers
Rising Inhaler Costs in Healthcare Systems
Inhaler prescriptions represent a significant and growing expense for healthcare systems. In the United States, Medicare spent $50.5 billion on inhalers between 2014 and 2018, with both the number of users and total expenditure increasing by over 120% during this period . Similarly, Medicaid spending on inhalers reached $26.2 billion from 2012 to 2018, with inhaled corticosteroid (ICS)-containing inhalers accounting for the largest share and experiencing a 607% growth in spending for certain classes . These trends highlight the increasing financial burden of inhaler therapies for chronic respiratory diseases.
Cost Comparison: Inhalers vs. Alternative Therapies
For patients with end-stage respiratory disease in hospice care, inhalers are notably more expensive than alternative delivery methods. The average cost per patient per claim per day was $10.64 for inhalers, compared to $3.28 for nebulized medications and $1.02 for oral corticosteroids. Additionally, inhaler use near the end of life leads to significant monetary waste due to unused doses, suggesting that switching to nebulized or oral medications could reduce costs and waste .
Impact of Inhaler Technique and Adherence on Costs
Incorrect inhaler technique and poor adherence are major contributors to increased healthcare costs. Poor technique with dry powder inhalers (DPIs) can account for 2.2–7.7% of direct costs in asthma and COPD management, translating to hundreds of millions of euros in avoidable expenses across Europe . In children, incorrect inhaler technique and higher asthma severity are linked to higher direct costs, emphasizing the importance of proper training and disease control .
Cost-Effectiveness of Digital and Smart Inhaler Technologies
Digital inhalers and connected inhaler systems (CIS) that monitor usage and provide feedback have shown promise in reducing costs and improving outcomes. In patients with difficult-to-treat asthma, digital inhalers can save over €3,000 ($3,377) per patient per year compared to usual care, with even greater savings over a 10-year period . Similarly, CIS for severe asthma patients can save £288 per patient per year and reduce exacerbations, resulting in cost savings of up to £19,100 per quality-adjusted life year (QALY) gained . For COPD, adherence-enhancing interventions using smart inhalers are also cost-effective, especially for patients with irregular use but good technique, with potential annual savings of €845 per person .
Cost-Effectiveness of Single-Inhaler Triple Therapies
Single-inhaler triple therapies for COPD and asthma have been found to be cost-effective compared to multiple-inhaler regimens. In the UK, single-inhaler triple therapy for COPD provided gains in life years and QALYs at a modest incremental cost, with cost-effectiveness ratios well within accepted thresholds . For uncontrolled asthma, single-inhaler triple therapy was also cost-effective or even cost-saving compared to multiple-inhaler options .
The Role of Generics and Market Dynamics
Despite the high spending on inhalers, the uptake of generic inhalers remains low. For example, less than 0.01% of Medicaid inhaler spending was on generics, indicating a significant opportunity to reduce costs by increasing the availability and use of generic options .
Conclusion
Inhaler therapies are a major and rising cost in the management of asthma and COPD. Key drivers of these costs include the choice of delivery method, inhaler technique, medication adherence, and the limited use of generics. Digital and smart inhaler technologies, as well as single-inhaler triple therapies, offer cost-effective solutions by improving adherence and reducing exacerbations. Addressing inhaler technique, promoting generics, and optimizing therapy choices are essential strategies for controlling inhaler-related healthcare expenditures.
Sources and full results
Most relevant research papers on this topic